Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
FGF5 Biologics Sequence Review Report 2026: Fibroblast growth factor 5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF5 Biologics Sequence Review Report 2026: Fibroblast growth factor 5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF3 Biologics Sequence Review Report 2026: Fibroblast growth factor 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF3 Biologics Sequence Review Report 2026: Fibroblast growth factor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF6 Biologics Sequence Review Report 2026: Fibroblast growth factor 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF6 Biologics Sequence Review Report 2026: Fibroblast growth factor 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAV Biologics Sequence Review Report 2026: Integrin alpha-V Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAV Biologics Sequence Review Report 2026: Integrin alpha-V Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAV protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD2 Biologics Sequence Review Report 2026: T-cell surface antigen CD2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD2 Biologics Sequence Review Report 2026: T-cell surface antigen CD2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD1A Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1a Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD1A Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1a Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB1 Biologics Sequence Review Report 2026: Integrin beta-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB1 Biologics Sequence Review Report 2026: Integrin beta-1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB2 Biologics Sequence Review Report 2026: Integrin beta-2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB2 Biologics Sequence Review Report 2026: Integrin beta-2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB3 Biologics Sequence Review Report 2026: Integrin beta-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB3 Biologics Sequence Review Report 2026: Integrin beta-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD4 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD4 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TLR3 Biologics Sequence Review Report 2026: Toll-like receptor 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TLR3 Biologics Sequence Review Report 2026: Toll-like receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TLR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL1 Biologics Sequence Review Report 2026: Growth-regulated alpha protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL1 Biologics Sequence Review Report 2026: Growth-regulated alpha protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →